Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the [...]
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvement Findings to form the basis [...]
HEIDELBERG, Germany, Oct. 24 (Korea Bizwire) — BioMed X announced today the launch of their first joint research project with Sanofi. As part of this, a new research group to be established at the BioMed X Institute in Heidelberg, Germany, will focus on the development of a versatile computational platform able to accurately predict the efficacy of [...]
SEOUL, Jan. 12 (Korea Bizwire) — South Korea’s biotech company ABL Bio Inc. said Wednesday it has entered a global license agreement worth US$1.06 billion with pharmaceutical giant Sanofi to develop and commercialize an antibody candidate to treat Parkinson’s disease. ABL301 is a preclinical antibody therapeutic under development as a potential treatment of synucleinopathy, including [...]
SAN DIEGO and PARIS, June 17 (Korea Bizwire) — Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular platform company, today announced that it has entered into an exclusive worldwide license agreement with Sanofi, a global biopharmaceutical company. This agreement provides RSF Bio with Sanofi’s rights to Ataciguat. [...]
Paris, April 28 (Korea Bizwire ) — Q1 2021 sales increase of 2.4% at CER driven by growth drivers Dupixent® and Vaccines Specialty Care sales grew 15.3%, due to strong Dupixent® performance (+45.6% to €1,047 million) and oncology launches Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere General Medicines core [...]
Paris, FRANCE, Feb. 5 (Korea Bizwire) - Q4 2020 sales growth(2) of 4.2% and business EPS growth of 9.8% at CER Specialty Care sales grew 18.3%, driven by strong Dupixent® performance (+54.2% to €982 million). Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. General Medicines declined 7.5%, reflecting lower [...]
Paris, France, Nov. 13 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announced that Sanofi has made a €50 million investment in Jeito Capital. The investment will be deployed by Jeito’s highly experienced team of pharmaceutical and biotech experts in line with its investment criteria to provide [...]
PARIS, FRANCE, Oct. 29 (Korea Bizwire) – Q3 2020 sales growth(2) driven by strong Dupixent® and flu vaccines demand. Net sales were €9,479 million, up 5.7%(2) at CER and down 0.2% on a reported basis. Specialty Care sales grew 23.8%, driven by strong Dupixent® performance (+68.6% to €918 million) and growth in all franchises. Vaccines sales up 13.6%, driven [...]
Paris, FRANCE, July 29 (Korea Bizwire) - Q2 2020 sales results reflect the strong performance of Dupixent® more than offset by COVID-19 related negative effects on Vaccines, General Medicines and CHC Net sales were €8,207million, down 4.9% on a reported basis and a decline of 3.4%(2) at CER. Specialty Care sales grew 17.4% driven by strong performance [...]